Claims
- 1. A compound of formula I:
- 2. A compound of formula II:
- 3. A compound of claim 1 having structural formula III:
- 4. A compound of claim 3, wherein:
R1 and R8 are each independently a lower alkyl group; and R11 is a C3-C8 cycloalkyl group.
- 5. A compound of claim 4, wherein R11 is a member selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- 6. A compound of claim 3, wherein:
R8 is a methyl group; p is an integer from 1-2; E is a member selected from the group consisting of: direct link 94J is a member selected from the group consisting of: 95G is a member selected from the group consisting of: 96
- 7. A compound of claim 1 having structural formula IV:
- 8. A compound of claim 7, wherein R1, R8 and R14 are independently selected from the group consisting of hydrogen and C1-C5 alkyl.
- 9. A compound of claim 7 having the following structural formula:
- 10. A compound of claim 3 having structural formula V:
- 11. A compound of claim 10 having the following structural formula:
- 12. A compound of formula VI:
- 13. A compound of claim 12 having the following structural formula:
- 14. A compound of claim 13, wherein:
p is an integer from 1 to 3; R23 is hydrogen; and R9 is C1-C3 alkyl.
- 15. A compound of claim 12 having structural formula VIb:
- 16. A compound of claim 1 selected from the group consisting of:
- 17. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a therapeutically acceptable carrier and a therapeutically effective amount of a compound of one of claims 1-16.
- 18. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of one of claims 1-16.
- 19. The method of claim 18 wherein the condition is selected from the group consisting of:
acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices.
- 20. A method for inhibiting the coagulation of a biological sample comprising the administration of a compound of one of claims 1-16.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/191,720 filed on Mar. 24, 2000, which is incorporated here in its entirety by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60191720 |
Mar 2000 |
US |